Navigation Links
Physicians Reconsider Implications of Enhance Trial
Date:2/7/2008

First Impact Report Reveals Shift in Prescribing Patterns As More MDs

Question Clinical Outcomes of Cholesterol-Reducing Drug

NEW YORK, Feb. 7 /PRNewswire/ -- Despite the controversy surrounding the release of the preliminary ENHANCE trial results on January 14, 2008, physicians are less concerned now -- roughly three weeks later -- about the trial results than they were initially, according to a pivotal FirstImpact Report issued today by FirstWord Publishing, publishers of the FirstWord newsletter, the world's leading source of news for the pharmaceutical industry.

The report, FirstImpact: ENHANCE trial results -- physicians evolving reactions, is based on surveys with general practitioners and cardiologists. The ENHANCE clinical trial results showed that Vytorin, a combination of Zetia and Zocor, is no more effective than Zocor in reducing plaque formation in patients with a condition that affects only about 0.2 percent of the population overall.

In the 48 hours after Merck/Schering-Plough released the preliminary results of the ENHANCE clinical trial, 82 percent of surveyed physicians responded that the results would have an impact on their prescribing decisions. A follow-up survey conducted by FirstImpact Reports on January 31 showed that this impact had decreased to 60 percent. Nonetheless, the FirstImpact survey also found that a large group of physicians continued to have negative reactions to the ENHANCE trial.

"There has been considerable speculation about the potential shifts in prescriptions of Vytorin and Zetia as a result of the ENHANCE trial results. But ultimately, it is the attitudes and treatment intentions of practicing physicians that determine how significantly prescriptions for these products will continue to be affected by the fallout of the ENHANCE trial," said Dominique Balas, president of FirstImpact Reports. She continues, "Our research found that while physicians' prescribing intentions have st
'/>"/>

SOURCE FirstImpact Reports
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
6. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
7. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
11. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... the Prox1 gene is a two-way switch that, if turne...programmed so that they lose their identity and be...MEMPHIS, Tenn., Dec. 1 ...al have discovered that a certain differentiated c...t requires the constant expression of a gene calle...
(Date:12/1/2008)...rk, December 1 Following...ntent to procure an MVA-based,third generation s...ces,Canada, on behalf of the Canadian Department ...varian Nordic for the delivery of IMVAMUNE(R). , ...UNE(R) as part of the,country,s bio-preparedness ...
(Date:12/1/2008)...RNewswire-FirstCall/ -- Vical Incorporated (Nasdaq...illion milestone payment from Merck & Co., Inc... clinical trial of an investigational plasmid DNA ...sed on Vical,s DNA gene delivery technology and en...T). hTERT is the subject of separate license agree...
(Date:11/28/2008)...y, November 28 German biotech comp...specialized HIV monitoring and,AIDS patient follo...ries. In,the year 2008, 2.5 million patient tests...d highly affordable "CyFlow" system, supporting al...AIDS. Due to introduction of the,Partec innovatio...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2First of its kind study compares high school knee injuries by sport and gender 20036 1First of its kind study compares high school knee injuries by sport and gender 20036 2Direct Response TV Course on Nutraceutical Cosmeceutical Products to Premiere in New York City 20034 1Direct Response TV Course on Nutraceutical Cosmeceutical Products to Premiere in New York City 20034 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 1Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2169 6American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 20032 1American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 20032 2
...ire-USNewswire/ -- Democratic,National Committee C... today after President Bush once again put politic...ch Enhancement Act of,2007. , The legislation, pro...tem cell research, has the overwhelming support of... Senate with,bipartisan support. A recent USA Toda...
...rs funded in part by the,National Institutes of He...st cases of Goltz syndrome, a rare skin disorder,t... cases appear to result from a defect in the gene ...ded to make a protein,referred to by researchers ...st identified in fruit flies, was named for the,pa...
Other Medicine Technology:Dean: President Bush Has Turned His Back on the American People 2Researchers Discover Gene For Rare Skin Disorder 2Researchers Discover Gene For Rare Skin Disorder 3
(Date:12/1/2008)...wire/ -- Democratic National Committee Chairman Ho...memorating World AIDS Day on its 20th Anniversary:.../prnh/20080519/DNCLOGO ) , , "It,s been 20 ... have made strides, much work remains to be done t...obal strategy. We must focus not only on preventi...
(Date:12/1/2008)...e/ -- MassMutual Retirement Services Division has ...g nonprofit business. Nonprofit activity has more ..., Dan Darby joined MassMutual on December 1 as...n. He reports to M. Palmer Whitney, national manag...etirement Services Division, who will continue to ...
(Date:12/1/2008)...so trigger acute organ failure, study says , ...ics are the single largest class of drugs that cau... researchers say. , The condition accounts for ...n the United States and is the most common cause o...sed by a wide range of prescription and nonprescri...
(Date:12/1/2008)...TSD) affects as many as one in five of all America...ssault, war or terrorism. It has emotionally paral...milies. , There is no broadly accepted treatmen...rder, but thanks to a Tel Aviv University research... around the corner. , Prof. Joseph Zohar from th...
Breaking Medicine News(10 mins):Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
...ers of the popular Ortho Evra birth control patch ...risk of blood clots and other serious side effects...od and Drug Administration has warned. According ...egulators and patch-maker Ortho McNeil, a Johnson ...
...new study appearing in the November 1, 2005 issue ...at a new gene profile may help in predicting how p... to aggressive chemotherapy. // In many patients w...irst grade chemotherapy usually shows an effect in...
...definitive link has been established between age-r...isms underlying the disease process. The finding h...rium //called Chlamydia pneumoniae in the diseased... is also notable that the microorganism is associa...
...e mother of a 17-year-old teenager named Daniel Hi...uced to tears after a coroner's jury returned the ... in December 2002 - two months after he got his li... He was admitted to a hospital after vomiting and ...
Other Medicine News:Health News:FDA Warns Against Birth-Control Patch 2Health News:Genetic Profile To Predict Ovarian Cancer Prognosis 2
...tem for microscope-aided repair of herniated inter...res with reduced patient trauma. Used in lumbar mi...l HNP. The retractor is designed to provide low pr...hanced visualization through the use of titanium b...
Dualswitch Valve for the Treatment of Hydrocephalus. Dualswitch-Valve keeps the IVP within physiological limits independent of the posture of the patient. Special design permits the use of very stro
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position.
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch
Medicine Products: